Investigating a Vaccine Against COVID-19 (COV002): A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19

Summary: There are no currently licensed vaccines for COVID-19. This study will enable us to assess how well people of all ages can be protected from COVID-19 with this new vaccine called ChAdOx1 nCoV-19. It will also give us valuable information on safety aspects of the vaccine and its ability to generate good immune responses against COVID-19. The researchers will enrol small numbers of older adults (56-70 years, then 70+ years) before expanding to large numbers of adults across all ages (18+ years). After this we will also assess the vaccine in a small group of children (5-12 years). There will be between 9 and 14 visits over 12 months with a blood test at each visit. Participants will receive one or two doses of the new COVID-19 vaccine or a licensed vaccine which has been given routinely to teenagers in the UK since 2015 to protect against meningitis and sepsis. Some participants may be asked to complete an electronic diary for 7 days after each vaccine and update the diary if they have any illness for a month after vaccination. Description: This study will enableresearchers to assess how well people of all ages can be protected from COVID-19 with a new vaccine called ChAdOx1 nCoV-19. It will provide valuable information on safety aspects of the vaccine and its ability to generate good immune responses against the virus. The researchers will enrol small numbers of older adults (56-70 years, then 70+ years) before expanding to large numbers of adults across all ages (18+ years). After this we will also assess the vaccine in a small cohort of children (5-12 years).